Responsibilities

• Support development of an integrated lifecycle strategy for a rare disease therapy, including new indications and additional evidence to broaden utility within current population
• Lead market assessments and prioritization of new indications and evidence generation investments based on sound strategic and financial rationale.
• Partner with Medical Affairs, Clinical, Regulatory, and Market Access around the design of potential Phase IV studies, RWE initiatives, and additional clinical studies to support label expansion; provide commercial perspective aligned with brand strategy to guide decision making
• Partner with Market Access to strengthen the payer value proposition, ensuring evidence generation reinforces payer narratives and aligns with access strategy.
• Partner with Medical Affairs to shape the KOL engagement strategy that informs evidence generation and lifecycle planning.
• Synthesize insights from KOLs to guide strategic priorities and refine the integrated lifecycle strategy.
• Ensure consistent pull‑through of brand messaging within current indication by partnering with peer to peer and omnichannel teams to align content, tone, and strategic intent
• Support advisory boards and insight‑gathering activities to ensure brand strategy and messaging reflects real‑world clinical practice and emerging mindset.
• Support development of strategic marketing plans to achieve business objectives, including participation in strategy development and messaging evolution for HCP and patient audiences.
• Ensure timely understanding, measurement and evaluation of brand performance and work collaboratively within the marketing team to modify tactical plans as needed.